For the treatment of cutaneous candidiasis, dermatophytosis and pityriasis versicolor.
For the treatment of mycotic vulvovaginitis and mycotic balanitis.
Vaginitis due to Candida albicans and other yeasts.
Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Arcutis Biotherapeutics, Inc. announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase III studies evaluating roflumilast cream (ARQ 151) as a potential topical treatment for plaque psoriasis.
Arcutis Biotherapeutics, Inc. announced that it has commenced pivotal Phase III clinical trials evaluating topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis (AD).
Incyte announced that the FDA has approved Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.